Compare DLPN & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLPN | RLYB |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.8M | 24.1M |
| IPO Year | N/A | 2021 |
| Metric | DLPN | RLYB |
|---|---|---|
| Price | $1.65 | $0.64 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 34.5K | ★ 202.1K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $53,371,115.00 | $674,000.00 |
| Revenue This Year | $9.05 | N/A |
| Revenue Next Year | $15.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 3.86 | ★ 12.71 |
| 52 Week Low | $0.75 | $0.22 |
| 52 Week High | $1.88 | $1.24 |
| Indicator | DLPN | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 48.38 | 54.42 |
| Support Level | $1.60 | $0.59 |
| Resistance Level | $1.84 | $0.68 |
| Average True Range (ATR) | 0.12 | 0.04 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 31.58 | 44.50 |
Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.